Document is current

Article History

Received: 12 January 2024

Accepted: 22 March 2024

First Online: 17 April 2024

Declarations

:

: T. Yamatsuji reports grants from MSD, Chugai Pharmaceutical, Takeda Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Kaken Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eli Lilly Japan, Shionogi Pharma Co., Ltd., Taiho Pharmaceutical, Bayer Yakuhin, Ltd., and Otsuka Pharmaceutical Co., Ltd., and personal fees from Yakult Honsha Co., Ltd., outside of the submitted work. N. Takigawa reports grants and personal fees from Eli Lilly Japan, AstraZeneca, Daiichi-Sankyo Co., Ltd., Chugai Pharmaceutical, Taiho Pharmaceutical, Pfizer Inc., Japan, Boehringer-Ingelheim Japan, and Ono Pharmaceutical; grants from Kyowa Hakko Kirin, Nippon Kayaku Co., Ltd., and Takeda Pharmaceutical Co., Ltd.; and personal fees from MSD and Bristol-Myers Squibb Company, Japan, outside of the submitted work. No disclosures have been reported by the other authors. T. Fukazawa reports personal fees from Boehringer-Ingelheim, Japan.

: The research protocol received approval from the Ethics Committee of the Kawasaki Medical School, with the assigned reference number 3171–5. All studies involving the use of animals were approved by the animal research committee of Kawasaki Medical School (Reference Number: 23–047). The care and use of animals were conducted in accordance with the committee regulations.

: The patient who participated in the present study signed an informed consent form approved by the responsible authority.

: Correspondence and requests for materials should be addressed to T.F.